What is the total financial value of Novartis' acquisition of Myricx Bio, and how is it structured?

Novartis agreed to acquire Myricx Bio for up to $1.5 billion, comprising an upfront payment of $1.1 billion and up to $400 million in potential milestone payments.

Why is Novartis acquiring Myricx Bio, and what therapeutic area does the company focus on?

Novartis is acquiring Myricx Bio to advance its strategy of scaling innovative platforms—such as antibody-drug conjugates (ADCs)—for cancer treatment, specifically to address the need for new payload mechanisms that overcome resistance and expand patient impact.

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

Jul 5, 2026

Novartis agreed to acquire UK biotech Myricx Bio for up to $1.5 billion to expand its antibody-drug conjugate cancer treatments, with the deal set to close in the second half of 2026.

reuters

2026-07-05

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

2026-07-19

Novartis faces drug pipeline test with valuation premium in focus

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

FAQ